GEMP vs. EGRX, AEON, CARM, KRON, CALC, MURA, ANEB, IMMX, ELDN, and TLSA
Should you be buying Gemphire Therapeutics stock or one of its competitors? The main competitors of Gemphire Therapeutics include Eagle Pharmaceuticals (EGRX), AEON Biopharma (AEON), Carisma Therapeutics (CARM), Kronos Bio (KRON), CalciMedica (CALC), Mural Oncology (MURA), Anebulo Pharmaceuticals (ANEB), Immix Biopharma (IMMX), Eledon Pharmaceuticals (ELDN), and Tiziana Life Sciences (TLSA). These companies are all part of the "medical" sector.
Eagle Pharmaceuticals (NASDAQ:EGRX) and Gemphire Therapeutics (NASDAQ:GEMP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, community ranking, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.
85.4% of Eagle Pharmaceuticals shares are held by institutional investors. Comparatively, 17.5% of Gemphire Therapeutics shares are held by institutional investors. 28.9% of Eagle Pharmaceuticals shares are held by insiders. Comparatively, 22.7% of Gemphire Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, Eagle Pharmaceuticals had 1 more articles in the media than Gemphire Therapeutics. MarketBeat recorded 1 mentions for Eagle Pharmaceuticals and 0 mentions for Gemphire Therapeutics. Gemphire Therapeutics' average media sentiment score of 0.94 beat Eagle Pharmaceuticals' score of 0.00 indicating that Eagle Pharmaceuticals is being referred to more favorably in the media.
Eagle Pharmaceuticals has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Comparatively, Gemphire Therapeutics has a beta of 2.82, indicating that its stock price is 182% more volatile than the S&P 500.
Eagle Pharmaceuticals currently has a consensus target price of $17.00, suggesting a potential upside of 257.14%. Given Gemphire Therapeutics' higher possible upside, equities analysts plainly believe Eagle Pharmaceuticals is more favorable than Gemphire Therapeutics.
Eagle Pharmaceuticals received 123 more outperform votes than Gemphire Therapeutics when rated by MarketBeat users. Likewise, 70.67% of users gave Eagle Pharmaceuticals an outperform vote while only 69.98% of users gave Gemphire Therapeutics an outperform vote.
Gemphire Therapeutics' return on equity of 0.00% beat Eagle Pharmaceuticals' return on equity.
Eagle Pharmaceuticals has higher revenue and earnings than Gemphire Therapeutics.
Summary
Eagle Pharmaceuticals beats Gemphire Therapeutics on 11 of the 12 factors compared between the two stocks.
Get Gemphire Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GEMP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GEMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gemphire Therapeutics Competitors List
Related Companies and Tools
